ATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against REGENXBIO Inc. (NASDAQ: RGNX). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts concerning the efficacy and safety of its RGX-111 trial study, causing Plaintiff and other shareholders to purchase REGENXBIO’s securities at artificially inflated prices.
If you purchased REGENXBIO shares between February 9, 2022 and January 27, 2026, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/regenxbio/ for more information.
The deadline to ask the court to be appointed lead plaintiff in the case is April 14, 2026.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
